Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CVRX NASDAQ:INGN NASDAQ:QTI NASDAQ:TLSI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVRXCVRx$8.00-4.2%$6.45$4.30▼$18.55$217.71M1.23308,475 shs358,405 shsINGNInogen$6.35-4.9%$6.64$5.70▼$13.33$179.61M1.66243,215 shs175,607 shsQTIQT Imaging$2.03+5.2%$1.09$0.35▼$0.84$55.08M-0.2181,094 shs43,853 shsTLSITriSalus Life Sciences$4.60-2.5%$5.22$3.50▼$6.04$178.60M0.552,332 shs30,922 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVRXCVRx-4.19%+17.13%+37.22%+28.00%-17.61%INGNInogen-4.94%-8.24%-3.79%-6.89%-33.99%QTIQT Imaging+5.18%-7.73%+162.27%+190.00%+198.05%TLSITriSalus Life Sciences-2.54%-5.93%-14.50%-19.86%-19.16%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCVRXCVRx2.9135 of 5 stars3.41.00.00.02.74.20.6INGNInogen4.253 of 5 stars3.34.00.03.91.41.71.3QTIQT ImagingN/AN/AN/AN/AN/AN/AN/AN/ATLSITriSalus Life Sciences3.0331 of 5 stars3.62.00.00.03.32.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVRXCVRx 2.86Moderate Buy$14.5081.25% UpsideINGNInogen 2.50Moderate Buy$11.0073.23% UpsideQTIQT Imaging 0.00N/AN/AN/ATLSITriSalus Life Sciences 3.25Buy$10.75133.70% UpsideCurrent Analyst Ratings BreakdownLatest QTI, CVRX, TLSI, and INGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/7/2025CVRXCVRxWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/16/2025INGNInogenB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.006/15/2025INGNInogenB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.005/22/2025INGNInogenNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Moderate Buy$12.005/9/2025CVRXCVRxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$20.00 ➝ $12.005/9/2025CVRXCVRxJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Underweight$15.00 ➝ $7.005/8/2025INGNInogenStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$10.00 ➝ $7.00(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVRXCVRx$51.29M4.07N/AN/A$2.93 per share2.73INGNInogen$335.70M0.51N/AN/A$7.30 per share0.87QTIQT Imaging$4.00M13.78N/AN/A($1.91) per share-1.06TLSITriSalus Life Sciences$29.43M5.91N/AN/A($0.83) per share-5.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVRXCVRx-$59.97M-$2.18N/AN/AN/A-97.49%-79.04%-42.37%8/4/2025 (Estimated)INGNInogen-$35.89M-$1.15N/AN/AN/A-8.08%-14.76%-9.01%8/7/2025 (Confirmed)QTIQT Imaging-$4.03MN/A0.00∞N/AN/AN/A-65.94%8/6/2025 (Estimated)TLSITriSalus Life Sciences-$30.05M-$1.12N/AN/AN/A-84.67%N/A-111.63%8/13/2025 (Estimated)Latest QTI, CVRX, TLSI, and INGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025TLSITriSalus Life Sciences-$0.22N/AN/AN/A$10.69 millionN/A8/5/2025Q2 2025INGNInogen-$0.25N/AN/AN/A$90.40 millionN/A8/4/2025Q2 2025CVRXCVRx-$0.52N/AN/AN/AN/AN/A5/15/2025Q1 2025TLSITriSalus Life Sciences-$0.20-$0.33-$0.13-$0.39$9.04 million$9.17 million5/8/2025Q1 2025CVRXCVRx-$0.56-$0.53+$0.03-$0.53$14.68 million$12.35 million5/7/2025Q1 2025INGNInogen-$0.52-$0.25+$0.27-$0.25$79.57 million$82.28 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCVRXCVRxN/AN/AN/AN/AN/AINGNInogenN/AN/AN/AN/AN/AQTIQT ImagingN/AN/AN/AN/AN/ATLSITriSalus Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVRXCVRx0.7114.8213.45INGNInogenN/A3.072.67QTIQT ImagingN/A1.060.48TLSITriSalus Life SciencesN/A2.141.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVRXCVRx75.27%INGNInogen89.94%QTIQT Imaging24.19%TLSITriSalus Life Sciences2.58%Insider OwnershipCompanyInsider OwnershipCVRXCVRx13.90%INGNInogen1.46%QTIQT Imaging75.40%TLSITriSalus Life Sciences27.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVRXCVRx16026.07 million22.45 millionOptionableINGNInogen1,03026.89 million26.49 millionOptionableQTIQT ImagingN/A27.13 million6.68 millionN/ATLSITriSalus Life Sciences10637.84 million27.43 millionNot OptionableQTI, CVRX, TLSI, and INGN HeadlinesRecent News About These CompaniesTriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System - Business WireJune 25, 2025 | businesswire.comTriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital StructureJune 23, 2025 | businesswire.comTriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. PatienceMay 30, 2025 | businesswire.comJodi Devlin Sells 4,764 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) StockMay 22, 2025 | insidertrades.comTriSalus outlines at least 50% revenue growth for 2025 as new Medicare code expands addressable marketMay 15, 2025 | msn.comTriSalus Life Sciences, Inc. (TLSI) Q1 2025 Earnings Conference Call TranscriptMay 15, 2025 | seekingalpha.comTriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue EstimatesMay 15, 2025 | zacks.comTriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 GuidanceMay 15, 2025 | businesswire.comTriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference CallMay 12, 2025 | businesswire.comTriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial ResultsApril 30, 2025 | finance.yahoo.comTriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock?April 9, 2025 | zacks.comTriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock?April 9, 2025 | zacks.comTriSalus Life Sciences: Optimistic Guidance For 2025, But There Are Still RisksMarch 30, 2025 | seekingalpha.comTrisalus outlines 50% revenue growth target for 2025 driven by TriNav expansion and new market penetrationMarch 27, 2025 | msn.comTriSalus Life Sciences’ Q4 Loss Exceeds Projections, Revenue Tops Estimates – Retail Stays PessimisticMarch 27, 2025 | msn.comTriSalus Life Sciences, Inc. (TLSI) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comTriSalus Life Sciences, Inc. (TLSI) Reports Q4 Loss, Tops Revenue EstimatesMarch 27, 2025 | zacks.comTriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business UpdateMarch 27, 2025 | businesswire.com3 Stocks With Robust Growth Outlooks Insiders Are Buying (TLSI)February 19, 2025 | insidertrades.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) CFO Purchases $33,900.00 in StockFebruary 7, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQTI, CVRX, TLSI, and INGN Company DescriptionsCVRx NASDAQ:CVRX$8.00 -0.35 (-4.19%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$8.00 0.00 (0.00%) As of 07/18/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Inogen NASDAQ:INGN$6.35 -0.33 (-4.94%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$6.42 +0.08 (+1.18%) As of 07/18/2025 05:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.QT Imaging NASDAQ:QTI$2.03 +0.10 (+5.18%) As of 07/17/2025QT Imaging Holdings, Inc. engages in the research, development, and commercialization of body imaging systems for detection, diagnosis, monitoring, and treatment of diseases. The company offers QT Ultrasound Breast Scanner, an ultrasonic imaging system that provides reflection-mode and transmission-mode images of a patient's breast. QT Imaging Holdings, Inc. was founded in 2011 and is based in Novato, California.TriSalus Life Sciences NASDAQ:TLSI$4.60 -0.12 (-2.54%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$4.62 +0.02 (+0.43%) As of 07/18/2025 05:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
